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Poster Session I 63(n 5 81) or a double (n 5 23) unrelated UCBT for an advanced
lymphoid malignancy. Sixty-three patients had a non-Hodgkin
lymphoma (18 diffuse large B-cell lymphoma, 10 follicular lym-
phoma, 8 mantle cell lymphoma, 8 peripheral T-cell lymphoma,
14 other T-cell lymphomas, 5 other B-cell lymphomas), 28 had
Hodgkin lymphoma, and 13 had B-cell chronic lymphocytic leuke-
mia (CLL). The majority of patients (85%) had advanced disease
(relapse, refractory disease, partial remission or $3rd complete re-
mission), and 54% had a prior autologous transplant. Based on an-
tigen-level HLA-A and B and allele-level HLA-DRB1 typing, cord
blood units were matched (9%) or mismatched at 1 (26%), 2 (59%)
or 3 (6%) antigens. The median number of cells infused was 2.4 
107 total nucleated cells (TNC)/kg for single transplants and 3.1 
107 TNC/kg for double transplants. Conditioning regimen varied
according to the transplant center, but 62% received a reduced-in-
tensity conditioning (RIC). GVHD prophylaxis was achieved with
cyclosporin and MMF in 48% of cases. Median follow-up time
for survivors was 14 months. The probability of engraftment at
day 60 was 86%, with a median time to engraft of 20 days (3–54).
In a multivariate analysis, a higher cell dose (2.5  107 TNC/kg)
was significantly associated with the neutrophil engraftment (p 5
0.04). Grade II-IV acute graft-versus-host disease (GVHD) was ob-
served in 24% of the patients. Transplant-related mortality (TRM)
was 34% at 6 months. In a multivariate analysis, TRM was signifi-
cantly lower for patients with B-cell malignancies (B-cell non-
Hodgkin lymphomas and CLL) as compared to those with Hodgkin
or T-cell lymphomas (21% vs. 49%; p 5 0.005), patients who re-
ceived TBI (25% vs. 49%; p 5 0.04). Disease free survival (DFS)
at 1 year was 40%. In a multivariate analysis, DFS was significantly
better for patients with B-cell malignancies (54% vs. 21%; p 5
0.006) and patients who received TBI (49% vs. 23%; p 5 0.001).
In conclusion, UCBT is a valuable alternative for patients with ad-
vanced non-Hodgkin lymphoma and CLL. B-cell malignancies and
the use of TBI are associated with a significantly better outcome.
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Background: Severe renal failure requiring hemodialysis (HD)
complicates multiple myeloma (MM) in about 3% of cases. Al-
though MM is not a contraindication to chronic dialysis, survival
of MM patients on dialysis is lower than for other conditions such
as diabetes. High dose chemotherapy and autologous stem cell
transplantation (ASCT) is feasible and effective in MM patients
on HD based on small, single center studies. Methods: We con-
ducted a retrospective cohort study of U.S. Medicare primary payer
dialysis patients with multiple myeloma as cause of end stage renal
disease in the U.S. Renal Database System (USRDS) from January
1999 through December 2004 with follow-up through September
2005. Medicare claims for ASCT were based on ICD-9 codes. Lo-
gistic regression was used to assess factors independently associated
with ASCT. Cox time-dependent regression was used to test
whether ASCT was independently associated with survival in this
cohort. Results: There were 3,307 MM patients, of whom 48
(1.5%) underwent ASCT. The mean age of ASCT patients was
60.9 yrs compared to 72.2 yrs in non-ASCT patients (p\ 0.001).
Factors that favored receiving ASCT by logistic regression were:
younger age, higher serum albumin, lower hematocrit and more re-
cent initiation of HD. Factors associated with survival (adjusted
hazard ratios with 95% CI) include ASCT (0.598, 0.352–1.017), Af-
rican-American (0.866, 0.777–0.964), albumin (0.86, 0.804–0.919),
hematocrit, (0.987, 0.979–0.995), age (1.017, 1.012–1.022), and
year of HD initiation, (0.848, 0.822–0.875). The 2-year survival
for ASCT patients was 67.4% and for non-ASCT patients was
24.5%. Conclusions: MM patients on HD rarely undergo
ASCT. The survival of MM patients on HD who do not receive
a transplant is poor. The survival of MM patients on HD who un-
dergo ASCT appears comparable to non-HD patients. Hemodialy-
sis should not be an absolute contraindication to ASCT in MM.170
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Background: Allogeneic hematopoietic cell transplantation
(HCT) following nonmyeloablative conditioning may be used
with lower transplant-related mortality (TRM) in elderly patients
(pts) and/or those with comorbidities. In this approach anti-tumor
activity relies on graft-versus-tumor effects. Here we analyzed out-
comes of nonmyeloablative allografts from HLA-identical sibling
performed by a multicenter consortium in pts with multiple mye-
loma (MM) with a median follow up (FU) of 5 years(y). Patients:
Between March 1998 and February 2007, 133 pts with stage II-III
MM received alloHCT following 2 Gy TBI 1/- fludarabine (48/
133 pts). Median age was 52 (range 31–71) y. Forty-eight and 7
pts (36% and 5%) were older than 55 and 65 y, respectively, and
43% had HCT specific comorbidity scores .1. Median number
of prior treatments was 1(range 1–6) and 44 pts (33%) received 2
or more lines of therapy. One hundred two pts (77%) received their
allografts as consolidation following cytoreductive autografts (con-
ditioning in 97% of pts: melphalan 200 mg/m2). Postgrafting im-
munosuppression was mycophenolate mofetil (MMF) and
cyclosporine (n5 116, 87%) or tacrolimus (n5 17, 13%). At allog-
rafting 86 pts (65%) had chemoresponsive disease with 33 and 53
pts (25% and 40%) in complete (CR) and partial remission (PR), re-
spectively, while 32 and 15 pts (24% and 11%) had chemorefractory
and progressive disease respectively. Results: Median FU for sur-
viving pts was 5(range 0.3–8.5)y. Fifty four(41%) and 12 pts (9%)
had grade 2 to 4 and 3 to 4 acute graft-versus-host-disease
(GVHD); 86 pts (65%) had extensive chronic GVHD. The overall
response rate was 89%, with 73(55%) and 46(34%) pts achieving
CR and PR, respectively. Median time to progression was 3.6 y. Me-
dian progression-free survival (PFS) was 2.7 y, and 5-y estimated
PFS was 28%. Nonrelapse mortalities (NRM) at 100 days, 1 and
5 y were 1%, 13% and 24%. Median overall survival (OS) was
reached after 6.2 y, and 5-y estimated OS was 54%. In the subset
of 102 pts who received a tandem auto/allografts, the median time
to progression was 4 y, median PFS was 3 y while median OS has
not been reached. In this group estimated PFS and OS at 3 and 5-
years were 69% and 40%, 80% and 55% respectively. Conclusion:
Nonmyeloablative allografting, in particular as part of a planned
tandem auto/allo HCT protocol, is a treatment option for MM
pts with HLA identical siblings. Future studies are aimed at improv-
ing long-term disease control and reducing GVHD.171
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION HAS CU-
RATIVE POTENTIAL FOR CHEMOREFRACTORY NON-HODGKIN LYM-
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Background: Autologous hematopoietic stem cell transplanta-
tion (auto-HSCT) has been widely used in patients with relapsed
chemosensitive non-Hodgkin lymphoma (NHL), but the prognosis
of patients with chemorefractory NHL remains poor. We com-
pared our experience of allo-HSCT with auto-HSCT for patients
with NHL. Methods: A total of 377 patients with NHL underwent
allo-HSCT (n 5 172, median age: 49 years old, range 18–71) or
auto-HSCT (n 5 205, median age: 56 years old, range 3–71) be-
tween 1996 and 2006 at University of Michigan. Patients who un-
derwent allo-HSCT for relapse after auto-HSCT were excluded.
Chemorefractory disease is defined as stable or progressive disease
